pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN
Regeneron UK
Regeneron UK Limited
NovaPharmaNews editorial coverage mentioning Regeneron UK — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- Tarrytown, USA
- Employees
- 16,715
- Programs
- 493
- Drugs
- 98
- Patents
- 837
News & analysis
NovaPharmaNews articles mentioning Regeneron UK — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Regeneron UK — regulatory, clinical, and market analysis.
Parabilis IPO Plans Following Regeneron Deal: What You Need to Know
Parabilis has announced its IPO plans just a day after the Regeneron deal, signaling a surge in listings. This article explores the implications for the pharmaceutical landscape.
Regeneron's Phase 3 Skin Cancer Trial Failure: Implications for LAG-3
Regeneron's recent Phase 3 trial failure for skin cancer highlights significant challenges in LAG-3 research. This article explores the implications for the pharmaceutical landscape.
Regeneron Secures $125M Parabilis Deal for Drug Targets
Regeneron has entered a significant $125M deal with Parabilis to target elusive drug targets. This partnership could reshape competitive dynamics in the pharmaceutical industry.
Regeneron's Phase 3 Skin Cancer Miss: Implications for LAG-3 Development
Regeneron's recent Phase 3 trial failure in skin cancer highlights ongoing challenges in LAG-3 research. This article examines the implications for the pharmaceutical industry.
Regeneron Immunotherapy Combo Fails in Melanoma Trial
Regeneron's recent melanoma trial results raise questions about the future of its immunotherapy combo. Analysts must assess the competitive landscape and investment implications.